Cardiovascular microphysiological systems (CVMPS) for safety studies – a pharma perspective-Reference-Cited by-同舟云学术

Cardiovascular microphysiological systems (CVMPS) for safety studies – a pharma perspective

Published:2021 Issue:3 Volume:21 Page:458-472
ISSN:1473-0197
Container-title:Lab on a Chip
language:en
Short-container-title:Lab Chip

Author:

Pointon Amy¹²³⁴⁵,Maher Jonathan⁶⁷⁸⁹,Davis Myrtle¹⁰¹¹⁹,Baker Thomas¹²¹³⁹,Cichocki Joseph¹⁴¹⁵⁹,Ramsden Diane¹⁶⁴⁵,Hale Christopher¹⁷¹⁸⁹,Kolaja Kyle L.¹⁹¹¹²⁰⁹,Levesque Paul¹⁰¹¹⁹,Sura Radhakrishna²¹²²²³⁹,Stresser David M.²⁴²⁵²²²³⁹^ORCID,Gintant Gary²⁶²⁷²²²³⁹

Affiliation:

1. Functional Mechanistic Safety

2. Clinical Pharmacology and Safety Sciences, R&D

3. AstraZeneca

4. Cambridge

5. UK

6. Translational Safety Sciences

7. Theravance Biopharma

8. South San Francisco

9. USA

10. Discovery Toxicology

11. Bristol-Myers Squibb Company

12. Eli Lilly, Lilly Corporate Center

13. Indianapolis IN 46285

14. Vertex Pharmaceuticals

15. Boston

16. Takeda Pharmaceuticals

17. Amgen Research

18. S. San Francisco

19. Investigative Toxicology and Cell Therapy

20. Summit NJ 07042

21. Preclinical Safety

22. AbbVie

23. N Chicago

24. Drug Metabolism

25. Pharmacokinetics and Translational Modeling

26. Integrative Pharmacology

27. Integrated Science and Technology

Abstract

The integrative responses of the cardiovascular (CV) system are essential for maintaining blood flow to provide oxygenation, nutrients, and waste removal for the entire body.

Publisher

Royal Society of Chemistry (RSC)

Subject

Biomedical Engineering,General Chemistry,Biochemistry,Bioengineering

Link

http://pubs.rsc.org/en/content/articlepdf/2021/LC/D0LC01040E

Reference106 articles.

1. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

2. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

3. Impact of a five-dimensional framework on R&D productivity at AstraZeneca

4. Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications

5. Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complex in vitro models positioned for impact to drug testing in pharma: a review;Biofabrication;2024-08-27

2. Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes;Cell Stem Cell;2024-03

3. Towards in vitro models for reducing or replacing the use of animals in drug testing;Nature Biomedical Engineering;2023-12-27

4. The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The IQ Microphysiological Systems Affiliate Survey and Commentary;Drug Metabolism and Disposition;2023-12-12

5. Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development;Advanced Biology;2023-10-09